Discover 151 paid clinical trials in Augusta, Maine. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 151
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
for
Non-small Cell Lung Cancer (NSCLC)
Location: South Portland ME, Boston MA, Moncton, Halifax,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT07291037
Phase3, Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
for
Breast Cancer, Locally Advanced Breast Cancer,
Location: Scarborough ME, Burlington MA, New Haven CT, Sayre PA,
Sponsor: Olema Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT07085767
Phase3, Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
for
Endometrial Cancer, Malignant Solid Tumour
Location: Scarborough ME, Stony Brook NY, White Plains NY,
Sponsor: AstraZeneca
Sex: Female
Age: 18+
Code: NCT07044336
Phase3, Recruiting
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
for
Metastatic Head-and-neck Squamous-cell Carcinoma,
Location: South Portland ME, Boston MA, Montreal, New Haven CT,
Sponsor: AVEO Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT06064877
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
for
Non-squamous Non-small Cell Lung Cancer
Location: South Portland ME, Saint John, Montreal, Saint-Jerôme,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06627647
Phase3, Recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
for
Cardiovascular Disease and Lipoprotein(a)
Location: Scarborough ME, Lebanon NH, Boston MA, Montreal, Quebec,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18 - 70+
Code: NCT07517263
Phase3, Recruiting
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
for
Atrial Fibrillation
Location: Scarborough ME, Burlington MA, Boston MA, Providence RI,
Sponsor: Johns Hopkins University
Sex: All
Age: 22 - 70+
Code: NCT05836987
Phase3, Recruiting
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
for
Endometrial Cancer
Location: Scarborough ME, Sherbrooke, Boston MA, Providence RI,
Sponsor: Merck Sharp & Dohme LLC
Sex: Female
Age: 18+
Code: NCT06952504
Phase3, Recruiting
EffectiveNess and SAfety of Small ANeurysm COiling Trial
Location: Scarborough ME, Sherbrooke, Lebanon NH, Boston MA,
Sponsor: Children's Oncology Group
Sex: All
Age: 3 - 29
Code: NCT06368817
Phase2, Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
for
Ovarian Cancer, Fallopian Tube Cancer,
Location: Scarborough ME, Providence RI, Montreal, New Haven CT,
Sponsor: Merck Sharp & Dohme LLC
Sex: Female
Age: 18+
Code: NCT06824467
Phase3, Recruiting
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
for
Stage I Mixed Cell Type Kidney Wilms Tumor,
Location: Scarborough ME, Sherbrooke, Lebanon NH, Boston MA,